Polarean Imaging (GB:POLX) has released an update.
Polarean Imaging plc, a leader in advanced MRI technology for lung function, has announced a fundraising initiative to generate at least $10 million through a combination of a placing, subscription, and open offer of new shares. The funds are earmarked for the commercial acceleration of its FDA-approved XENOVIEW product, further R&D, and general corporate purposes, with an aim to extend the company’s cash runway into Q1 2026. This capital raise is expected to significantly dilute current shares, offering new shares at a substantial discount.
For further insights into GB:POLX stock, check out TipRanks’ Stock Analysis page.
